Videos and Podcasts

30th Apr 20

Pharmaxis to progress myelofibrosis drug to Phase II following positive results

Gary Phillips tells Proactive's Andrew Scott they're progressing to a phase II study of its oral anti-fibrotic pan-Lysyl Oxidase (LOX) inhibitor PXS-5505 for treatment of the rare bone cancer, myelofibrosis (MF). The move comes on the back of positive results from its phase 1b trial and long-term toxicity studies.

Watch interview